| 1.68 0.23 (15.86%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.12 |
1-year : | 2.48 |
| Resists | First : | 1.82 |
Second : | 2.12 |
| Pivot price | 1.49 |
|||
| Supports | First : | 1.49 |
Second : | 1.29 |
| MAs | MA(5) : | 1.46 |
MA(20) : | 1.49 |
| MA(100) : | 1.76  |
MA(250) : | 1.53 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 59 |
D(3) : | 37.5 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 2.59 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TLSA ] has closed Bollinger Bands are 17.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
Mon, 19 Jan 2026
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million - marketscreener.com
Fri, 16 Jan 2026
Orrick Advises Tiziana Life Sciences on Nasdaq Registered Direct Offering of Up to Approximately $17.6 Million - orrick.com
Fri, 16 Jan 2026
Tiziana Life Sciences Closes $8.8 Million Direct Offering of 7.04 Million Shares - Intellectia AI
Fri, 16 Jan 2026
Tiziana Life Sciences closes $8.8 million registered direct offering - Investing.com
Fri, 16 Jan 2026
Tiziana leaders invest in $8.8M raise to finish Phase 2 na-SPMS, MSA trials - Stock Titan
Fri, 16 Jan 2026
Tiziana Life Sciences announces closing of oversubscribed $8.8M offering - Proactive financial news
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 120 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 46.5 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 1,570 (K) |
| Shares Short P.Month | 1,440 (K) |
| EPS | -0.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -83.8 % |
| Return on Equity (ttm) | -232.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -14 |
| PEG Ratio | 0 |
| Price to Book value | 21 |
| Price to Sales | 0 |
| Price to Cash Flow | -23.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|